ABL Diagnostics, a Euronext-listed company specializing in molecular biology assays and software for microbiology laboratories, has announced the release of new versions of its CE-IVD DeepChek® and ViroScore® software applications. These web-based and highly secure downstream analysis platforms are tailored to analyze Next Generation Sequencing (NGS) and Capillary Electrophoresis (SANGER) data from various sequencing systems.
The new versions, v3.30.115-ivdr, include advanced functionalities such as optimized algorithms for managing HIV-1 proviral DNA and expert systems for scrutinizing relevant genomic variations. They also integrate longitudinal or cumulative sample analyses from patients infected with the virus over time.
The systems are equipped with the latest clinical interpretation tools for reporting relevant information such as drug resistance assessment, liver disease prognosis, vaccine escape determination, and virulence, through consistently up-to-date guidelines.
In addition to the release of its new interactive MicrobioChek software (v2.4.4), ABL Diagnostics now offers a comprehensive portfolio of applications covering virology, bacteriology, and mycology. These fully integrated analysis software systems are coupled with a database allowing for reinterpretations of previously stored samples and are available worldwide in a matter of hours, either through local installations or a highly secure cloud service (HDS), in accordance with the highest international data protection regulations.
From raw sequence data to results, the DeepChek®, ViroScore®, and MicrobioChek® software platforms can be integrated with laboratory sequencing platforms, local Laboratory Information Systems (LIMS), and various Electronic Medical Record (EMR) systems, including Nadis, to offer a complete solution for optimizing disease management and targeting personalized medicine.
According to a report by 360 Research Reports, the global digital diagnostics market is projected to reach a market size of USD million by 2028, with ABL Diagnostics providing IT products and services to over 100 laboratories worldwide.
“Our company started as a software company in 2000. The experience and skills our entire team has developed over time is a real asset in offering the most advanced and innovative software systems for microbiology genotyping. We value the direct dialogue established with our partners to constantly integrate functionalities in line with end-users’ expectations,” said Mr. Matthieu Barralon, Head of Clinical at ABL SA.
About ABL Diagnostics:
ABL Diagnostics S.A. (ABLD) is a leading international company offering innovative and proprietary molecular biology assays and solutions for molecular detection and genotyping. Their portfolio includes assays for HIV, SARS-CoV-2, tuberculosis, viral hepatitis B and C, and other viral and bacterial targets. ABL Diagnostics also develops, manufactures, and markets kits for clinical specimen collection and digital solutions like Nadis®, an Electronic Medical Record system used in more than 200 hospitals in France. ABL Diagnostics is listed on Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6).
For more information, please visit www.abldiagnostics.com.
Contacts:
ABL Diagnostics
Ronan Boulme
General Manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
Forward-Looking Statement:
This press release contains certain forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers to be reasonable, but there can be no assurance that they will be verified. The occurrence of all or part of the risks mentioned in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022, and available on ABL Diagnostics’ website (www.abldiagnostics.com) could cause actual results, financial conditions, performance, or achievements to be materially different from the forward-looking statements contained in this press release. This press release and the information contained herein do not constitute an offer or invitation to sell or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
